11,925 trials (keyword fallback)
Asthma
Primary: Area Under the Plasma Concentration-time Profile From Time 0 the Last Quantifiable Concentration (AUC0-last) With Dose Normalization — 658; 700; 716; 748 pg.h/mL…
Adverse Drug Interactions
Primary: Midazolam Clearance (Pharmacokinetic Measure of Cytochrome P450 3A4 Activity) — 604; 552; 541; 156 ng*min/ml
HIV Prevention · Transgender Health
Primary: Tenofovir Diphosphate Concentration in Dried Blood Spots (DBS) — 973.5; 1078 fmol/punch
Contraception
Primary: Number of Subjects With Poor Cervical Mucus Scores During Treatment Period — 3; 11 Participants
Coronary Arterial Disease (CAD)
Primary: 888 Number of Participants With Major Adverse Cardiac Events (MACE) at 30 Days — 0 participants
Breast Cancer
Primary: Number of Participants of Clinically Relevant Toxicities (CRT) — 36; 13; 42; 26 Participants
Problematic AOD Use
Primary: Drug Use Disorders Identification Test-Consumption (DUDIT-C) — 4.8; 4.5 units on a scale
COVID-19
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity [Extrapolated] (AUC0-inf): ALG-097558 in Part A and Part C, Dabigatran (Total) in Plasma in Part B…
Oncolytic Virotherapy
Primary: Safety Parameters — 4; 3; 3; 3 Participants
Sickle Cell Anemia
Primary: Number of Participants With a Reduction in Invariant Natural-Killer T-Cell (iNKT Cell) Activation by 70% or More — 21; 10 Participants
Smoking Cessation
Primary: Change in the Skin Conductance Level, Caused by Smoking Cues, Measured Using Script Driven Imagery — 0.107; -0.040 µS — p=0.05
Cocaine Addiction
Primary: Drug Abstinence During Treatment and at Follow up Visits — 12; 25 percentage of drug abstinences
Healthy · Asthma
Primary: AUC Fluticasone Propionate (FP) — 188.2; 756; 978; 380.5 pg.h/ml — p=<0.05
Multiple Myeloma
Primary: Maximum Tolerated Dose (MTD) of Carfilzomib Plus Melphalan as Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Relapsed Multiple…
Anaphylaxis · Hypotension · Bronchospasm
Primary: Reduction in the Number and Timing of Anaphylactic Events in Subjects With a History of Frequent Idiopathic Anaphylaxis. — 32; 6 percentage of change of events